PPBT News and Press, Purple Biotech Ltd ADR (Sponsored) Level 3 From 02/01/24

2024-02-01 10:14:53 ET More on Purple Biotech Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial information for Purple Biotech Read the full article on Seeking Alpha For further details see: ...

REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, t...

Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech ...

This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class the...

2023-12-11 08:27:31 ET Losers: Cogent Biosciences ( COGT ) -31% . announces positive data from ongoing phase 2 APEX trial evaluating Bezuclastinib in patients . Purple Biotech Ltd ( PPBT ) -16% . Sphere 3D Corp ( ANY ) -14% . FLJ Group Ltd ( F...

2023-12-08 09:30:00 ET December 8, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Life Sciences, Fintech and Defense. Today's stocks have been added to our lists of fre...

2023-11-21 06:55:07 ET More on Purple Biotech Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial information for Purple Biotech For further details see: Purple Biotech GAAP EPS of -$0.23

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1 /2 Do s e Escalation Study Patients ’ E nrollment in the Phase 2 Randomized CM24 Pancreatic Cancer ...

Freightos Limited (CRGO) is expected to report $-0.14 for Q3 2023 Magyar Telekom Telecommunications ADR (MYTAY) is expected to report for Q3 2023 IMAC Holdings Inc. (BACK) is expected to report for Q1 2024 NewJersey Resources Corporation (NJR) is expected to report $0.3 for Q4 2023 ...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...